Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports and stock price the company's current number of shares outstanding is 4,428,059,072. At the end of 2026 the company had 4,428,059,072 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.